InterCure Ltd. INCR 深 沪
交易中 04-01 10:45:22 美东时间
0.7509
0.000
0.00%
华盛通- 最 高0.768
- 今 开0.768
- 成交量 768股
- 最 低 0.768
- 昨 收 0.7509
- 总市值 4106.02万
- 52周最高 1.7698
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.68
- 委 比 -42.86%
- 总股本 5468.13万
- 历史最高 271.8498
- 量 比 0.28
- 振 幅 0.00%
- 历史最低 0.68
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InterCure Ltd. Receives Nasdaq Non-Compliance Notice, Granted Until August 24, 2026 To Regain Compliance
InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced that on February 25, 2026 the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the
03-04 05:48
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
InterCure Ltd. received a notice from Nasdaq indicating its ordinary shares closed below $1.00 for 30 consecutive days, prompting a 180-day period to regain compliance by reaching $1.00 for 10 consecutive days. The company plans to evaluate a reverse share split to restore compliance and maintain listing on Nasdaq Global Market. Failure to meet requirements may lead to delisting.
03-03 21:46
InterCure Posts Preliminary NIS 265M Revenue For 2025, An 11% YoY Rise, With 2H Revenue Nearly 20% Higher Than Prior Year
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA.Revenue for 2025 represents an increase of
02-19 20:07
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
<p>InterCure reports preliminary 2025 revenue of NIS 265 million, a 11% increase over 2024, with significant growth in the second half. Adjusted EBITDA was positive for both halves, marking 12 consecutive positive results. The Company expanded into the German market for the first time and launched over 70 new SKUs. Key partnerships with Purplefarm, FN Canna, and Koots Canna, as well as acquisitions of Botanico and Cannasoul R&D, were also announc...
02-19 12:00
InterCure Enters Into Definitive Share Purchase Agreement And Collaboration Agreement With Cannasoul To Advance Cannabis Science And Pharmaceutical Innovation
Agreements formalize research partnership combining InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovationCollaboration comes amidst reports that the Trump
2025-11-03 21:43
Intercure H1 EPS $0.01 Up From $0.00 YoY, Sales $36.292M Miss $66.530M Estimate
Intercure (NASDAQ:INCR) reported quarterly earnings of $0.01 per share. This is a 700 percent increase over earnings of $0.00 per share from the same period last year. The company reported quarterly sales of $36.292
2025-10-09 16:32
InterCure reports NIS 130 million revenue and positive operating cash flow for first half 2025
InterCure Ltd. reported revenue of NIS 130 million for the first half of 2025. Adjusted EBITDA reached NIS 12.6 million, representing 10% of revenue, marking the eleventh consecutive half of positive ...
2025-10-08 20:50
InterCure Acquires ISHI to Expand U.S. Cannabis Market Reach
The latest update is out from Intercure ( ($IL:INCR) ). InterCure Ltd. announce...
2025-09-19 21:17
InterCure Acquires Botanico In All-Stock Deal Worth 4.92M Ordinary Shares To Expand Cannabis Portfolio
Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologiesTransaction comes as
2025-09-19 20:51
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
InterCure acquires ISHI, a leading cannabis company, gaining access to premium U.S. brands, advanced cultivation technologies, and exclusive partnerships. The acquisition aligns with InterCure's expansion strategy, leveraging potential U.S. regulatory shifts under the Trump administration, which is exploring cannabis rescheduling from Schedule I to Schedule III. This move strengthens InterCure's position to capitalize on the evolving U.S. cannabi...
2025-09-19 12:48
